Home/Filings/4/0001437749-21-027744
4//SEC Filing

Giaccia Amato 4

Accession 0001437749-21-027744

CIK 0001513818other

Filed

Dec 1, 7:00 PM ET

Accepted

Dec 2, 7:28 PM ET

Size

19.3 KB

Accession

0001437749-21-027744

Insider Transaction Report

Form 4
Period: 2021-11-30
Giaccia Amato
Director10% Owner
Transactions
  • Exercise/Conversion

    Common Stock

    2021-11-30$0.24/sh+500$120993,491 total
  • Sale

    Common Stock

    2021-11-30$3.22/sh39$126990,246 total
  • Exercise/Conversion

    Stock Option

    2021-11-3012,3500 total
    Exercise: $0.06From: 2018-10-12Exp: 2022-11-14Common Stock (12,350 underlying)
  • Exercise/Conversion

    Stock Option

    2021-11-305008,620 total
    Exercise: $0.24From: 2018-10-12Exp: 2024-12-31Common Stock (500 underlying)
  • Exercise/Conversion

    Common Stock

    2021-11-30$0.06/sh+12,350$741954,230 total
  • Sale

    Common Stock

    2021-11-30$3.22/sh252$811993,239 total
  • Exercise/Conversion

    Common Stock

    2021-11-30$0.24/sh+38,761$9,303992,991 total
  • Sale

    Common Stock

    2021-11-30$3.22/sh2,954$9,512990,285 total
  • Exercise/Conversion

    Stock Option

    2021-11-3038,7610 total
    Exercise: $0.24From: 2018-10-12Exp: 2024-09-30Common Stock (38,761 underlying)
Footnotes (4)
  • [F1]On November 14, 2012, Reporting Person was granted an option to purchase 32,500 shares of the common stock of Aravive at an exercise price of $0.02 per share. Pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of June 3, 2018 (the "Merger Agreement"), this option was converted into an option to purchase 12,350 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.06 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.
  • [F2]On October 1, 2014, Reporting Person was granted an option to purchase 102,000 shares of the common stock of Aravive at an exercise price of $0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 38,761 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.
  • [F3]On December 31, 2014, Reporting Person was granted an option to purchase 24,000 shares of the common stock of Aravive at an exercise price of $0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 9,120 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.
  • [F4]This transaction represents the sale of stock to cover the exercise price of the options.

Issuer

Aravive, Inc.

CIK 0001513818

Entity typeother

Related Parties

1
  • filerCIK 0001753058

Filing Metadata

Form type
4
Filed
Dec 1, 7:00 PM ET
Accepted
Dec 2, 7:28 PM ET
Size
19.3 KB